- Home
- MNDO vs SONN Comparison
MNDO vs SONN Comparison
Compare MNDO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- SONN
- Stock Information
- Founded
- MNDO 1995
- SONN N/A
- Country
- MNDO Israel
- SONN United States
- Employees
- MNDO N/A
- SONN N/A
- Industry
- MNDO EDP Services
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- SONN Health Care
- Exchange
- MNDO Nasdaq
- SONN Nasdaq
- Market Cap
- MNDO 24.2M
- SONN 21.4M
- IPO Year
- MNDO 2000
- SONN N/A
- Fundamental
- Price
- MNDO $1.17
- SONN $5.91
- Analyst Decision
- MNDO
- SONN Strong Buy
- Analyst Count
- MNDO 0
- SONN 1
- Target Price
- MNDO N/A
- SONN $20.00
- AVG Volume (30 Days)
- MNDO 31.3K
- SONN 960.3K
- Earning Date
- MNDO 11-04-2025
- SONN 08-13-2025
- Dividend Yield
- MNDO 18.49%
- SONN N/A
- EPS Growth
- MNDO N/A
- SONN N/A
- EPS
- MNDO 0.15
- SONN N/A
- Revenue
- MNDO $20,155,000.00
- SONN $1,000,000.00
- Revenue This Year
- MNDO N/A
- SONN $5,376.22
- Revenue Next Year
- MNDO N/A
- SONN N/A
- P/E Ratio
- MNDO $7.93
- SONN N/A
- Revenue Growth
- MNDO N/A
- SONN 1689.52
- 52 Week Low
- MNDO $1.02
- SONN $1.08
- 52 Week High
- MNDO $2.13
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- MNDO 40.43
- SONN 71.20
- Support Level
- MNDO $1.16
- SONN $2.71
- Resistance Level
- MNDO $1.22
- SONN $6.65
- Average True Range (ATR)
- MNDO 0.03
- SONN 0.66
- MACD
- MNDO 0.01
- SONN 0.33
- Stochastic Oscillator
- MNDO 16.67
- SONN 81.17
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.